Iovance Biotherapeutics (HAM:2LB) GF Value Rank: 2 (As of Jul. 07, 2026) — Near Median


HAM:2LB Iovance Biotherapeutics Inc HAM:2LB
44 GF Score
Price €3.78
GF Value €17.09
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics GF Value Rank?

Iovance Biotherapeutics HAM:2LB +2.44% 44 GF Value Rank is 2 as of Jul. 07, 2026, which is at its 10-year median of 2.00. GuruFocus rates HAM:2LB with a GF Score™ of 44/100 and a GF Value™ of €17.09 (Possible Value Trap). The stock has 2 warning signs investors should review.

Iovance Biotherapeutics has the GF Value Rank of 2.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Iovance Biotherapeutics GF Value Rank Related Terms


HAM:2LB vs SNDX, GLUE, TYRA: GF Value Rank Comparison

For the Biotechnology subindustry, Iovance Biotherapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's GF Value Rank falls into.


HAM:2LB
44GF Score
Iovance Biotherapeutics Inc HAM:2LB
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 2 mean?
Iovance Biotherapeutics (HAM:2LB) has a GF Value Rank of 2 as of Jul. 07, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Iovance Biotherapeutics and its competitors. This is near median its historical median of 2.00. Over the past decade, Iovance Biotherapeutics' GF Value Rank has ranged from 2.00 to 2.00.
Is Iovance Biotherapeutics' GF Value Rank too high?
Iovance Biotherapeutics' current GF Value Rank of 2 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 2.00. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' GF Value Rank compare to SNDX and GLUE?
Iovance Biotherapeutics' GF Value Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Iovance Biotherapeutics' own GF Value Rank has ranged from 2.00 to 2.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Iovance Biotherapeutics and its competitors. Iovance Biotherapeutics's current GF Value Rank is 2, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (HAM:2LB) is currently considered Possible Value Trap. The stock's GF Value™ is €17.09, compared to a current price of €3.78 — trading 77.9% below its estimated fair value. The current GF Value Rank is 2, which is near median its 10-year median of 2.00. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Iovance Biotherapeutics (HAM:2LB), the current GF Value Rank is 2 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iovance Biotherapeutics (HAM:2LB) Overvalued in 2026?

Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued. The current stock price of €3.78 is trading 77.9% below its estimated GF Value™ of €17.09. GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.

Key valuation signals for HAM:2LB:

  • GF Value Rank: 2 (near median its 10-year median of 2.00)
  • GF Value™: €17.09 vs. price of €3.78 (77.9% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the HAM:2LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score

Get the complete analysis for HAM:2LB

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.78
Price
€17.09
GF Value